20 Stocks Insiders Were Buying In Q1 2025

18. iBio, Inc. Common Stock (NASDAQ:IBIO)

Market Cap: $40.68 million

Number of insiders buying: 7

iBio is a biotechnology firm that leverages AI and advanced computational biology to develop biopharmaceuticals targeting cardiometabolic diseases, obesity, cancer, and other challenging conditions. The San Diego, California-based company uses proprietary 3D modeling and innovative drug discovery platforms to build a pipeline of novel antibody treatments for unmet medical needs. It is also one of the 12 best biotech penny stocks to invest in.

For the second quarter of fiscal 2025, iBio reported $200,000 in revenue and a net loss of $4.36 million, compared to a net loss of $4.49 million in the same period last year.

Earlier this year, iBio announced a collaboration with AstralBio Inc. to develop an antibody that targets Activin E, a potential treatment for cardiometabolic disorders and obesity, using iBio’s proprietary Machine-Learning Antibody Engine.

In January, seven insiders, including the company’s CFO, acquired approximately $654,995 worth of iBio shares at an average price of $2.72 per share. Year-to-date, the stock gained 59.59%, trading at $3.91 per share. Over the past 12 months, iBio shares rose 16.72%.

Based on the estimates of three analysts, iBio stock is a ‘Strong Buy’ with a price target of $4.87. The average price target suggests a 27.49% upside from the latest price.